Specialized therapies in targeted indications
We are committed to making a real difference in the lives of patients with selected endocrine and metabolic disorders. We do this through our unique offering of specialized therapies in targeted indications along with innovative drug delivery devices designed to maximize their full potential.
We are applying our expertise to treat growth hormone deficiency in children and adults, as well as other related metabolic disorders. In the United States, our growth hormone is helping patients with HIV-associated wasting and short bowel syndrome; also in the US, we offer EGRIFTA™ (tesamorelin for injection) as the first and only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy).